ArticleViruses2026
Defining Challenge Conditions for Nipah Virus in the Syrian Golden Hamster Model: Effects of Dose, Exposure Route and Viral Strain.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Nipah virus (NiV) is a highly pathogenic zoonotic virus for which no licensed vaccines or therapeutics are currently available, necessitating well-characterised animal models to support countermeasure development. This study aimed to establish an appropriate challenge dose in the Syrian golden hamster model at the UK Health Security Agency (UKHSA), incorporating both intraperitoneal (i.p.) and intranasal (i.n.) routes of infection and two clinically relevant strains, NiV-Malaysia (NiV-M) and NiV-Bangladesh (NiV-B). Due to a different challenge doses and susceptibilities of hamsters to NiV being reported in the literature, there is a prerequisite to define the model parameters upon establishment in a new facility. Dose-ranging studies were performed across multiple independent experiments assessing survival, clinical progression and histopathological outcomes. Challenge via the i.p. route produced consistent and severe disease using an infectious dose of 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.